Thanks to early detection and aggressive treatment for prostate cancer, 97 percent of all men diagnosed with the disease will survive at least 5 years and nearly 80 percent will survive at least a ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Details on ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

Prostate cancer is the second most common cancer in men, with over 288,000 new cases diagnosed each year. It’s also one of the most curable cancers if detected early. Now, a new imaging tool is ...

“This study adjusted for testosterone levels, which can influence PSA and outcomes, and still found a significant association. This strengthens the argument that PSA response to neoadjuvant therapy is ...

In cases of clinical equipoise, the highest MMAI score quartile could guide selective treatment intensification among patients with high-risk nonmetastatic prostate cancer. An artificial ...

The methods of diagnosing and treating localised prostate cancer has changed significantly in the last two decades.

Knowing the likely course of cancer can influence treatment decisions. Now a new prediction model published today in Lancet Oncology offers a more accurate prognosis for a patient's metastatic ...